AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2024
Jun 17, 2024
31580_dirs_2024-06-17_700dda03-1cf1-47bb-8e75-7c8a0ab27ec4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2024-06-13
Reporting Person: Schenkein David P (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-13 | Common stock | M | 3388 | — | Acquired | 126242 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-13 | Restricted stock units | $ | M | 3388 | Disposed | Common stock (3388) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common stock | 270772 | Indirect |
| Common stock | 79082 | Indirect |
Footnotes
F1: Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F2: Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F4: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested.